Zynerba Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Zynerba Pharmaceuticals is an American pharmaceutical company founded in 2007. It is headquartered in Devon, Pennsylvania. The company is developing a new generation of transdermal synthetic cannabinoids.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Zynerba Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Zynerba Pharmaceuticals cash flows

Report period2018 2019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Zynerba Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022 Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Zynerba Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Zynerba Pharmaceuticals assets
Zynerba Pharmaceuticals cash flows
Zynerba Pharmaceuticals news
12.10.2023
Harmony Biosciences has completed its acquisition of Zynerba Pharmaceuticals for $60 million, or $1.1059 per share. Zynerba shareholders were also entitled to an additional payment of up to $140 million, or $2.5444 per share, if certain conditions are met.
Source: {source} pictogram ir.harmonybiosciences.com
Pictogram next
14.08.2023
Harmony Biosciences is buying Zynerba Pharmaceuticals for $60 million, or $1.1059 per share. Shareholders will also be entitled to an additional payment of up to $140 million, or $2.5444 per share, if certain conditions are met. Completion of the transaction is expected to occur in the 4th quarter of 2023.
Source: {source} pictogram zynerba.com
Pictogram next
14.11.2022
Zynerba Pharmaceuticals' GAAP loss for 9 months of 2022 was $27.019 million, down 5.2% from $28.494 million in the previous year.
Source: {source} pictogram ir.zynerba.com
Pictogram next
10.08.2022
Zynerba Pharmaceuticals' GAAP loss for 6 months of 2022 was $18.344 million, up 2.4% from $17.912 million in the previous year.
Source: {source} pictogram ir.zynerba.com
Pictogram next
All Zynerba Pharmaceuticals news
General information
Company nameZynerba Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address80 W. LANCASTER AVENUE SUITE 300 DEVON PA 19333 484-581-7505
Mailing address80 W. LANCASTER AVENUE SUITE 300 DEVON PA 19333
Websitewww.zynerba.com